Andrew Hack - Aug 9, 2021 Form 4 Insider Report for DYNAVAX TECHNOLOGIES CORP (DVAX)

Role
Director
Signature
/s/ Andrew Hack
Stock symbol
DVAX
Transactions as of
Aug 9, 2021
Transactions value $
-$24,300,000
Form type
4
Date filed
8/11/2021, 06:26 PM
Previous filing
Aug 4, 2021
Next filing
Aug 27, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DVAX Common Stock Conversion of derivative security $0 +2.25M +26.38% $0.00 10.8M Aug 9, 2021 See footnotes F1, F2, F3
transaction DVAX Common Stock Sale -$24.3M -2.25M -20.88% $10.80 8.52M Aug 9, 2021 See footnotes F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DVAX Series B Convertible Preferred Stock Conversion of derivative security $0 -2.25K -54.32% $0.00 1.89K Aug 9, 2021 Common Stock 2.25M $0.00 See footnotes F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents securities held directly by Bain Capital Life Sciences Fund, L.P. ("BCLS") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities").
F2 Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F3 Each share of Series B Convertible Preferred Stock is convertible, at the option of the holder, into 1,000 shares of the Issuer's common stock and has no expiration date. The Series B Convertible Preferred Stock is not convertible if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of the Issuer's common stock then issued and outstanding immediately after giving effect to the conversion. On August 9, 2021, the Bain Capital Life Sciences Entities converted an aggregate of 2,249 shares of Series B Convertible Preferred Stock into an aggregate of 2,249,000 shares of the Issuer's common stock.